Tom 3, Nr 3 (2010)
Sprawozdanie z konferencji / Sprawozdanie
Opublikowany online: 2010-10-05
Wyświetlenia strony
467
Wyświetlenia/pobrania artykułu
5436
Terapia komórkowa ze szczególnym uwzględnieniem mobilizacji i pobierania komórek macierzystych do przeszczepienia
Journal of Transfusion Medicine 2010;3(3):99-105.
Streszczenie
Brak
Referencje
- Schlenke P, Mertens A, Ahlke C. How do I collect and process stem cells? ISBT Science Series. 2010; 5(n1): 136–140.
- Humpe A, Buwitt-Beckmann U, Gramatzki M. When do I (not) release cellular products? ISBT Science Series. 2010; 5(n1): 141–147.
- Richter E, Tapernon K, Friedrich AW, et al. Sterility testing of blood stem cell products is possible in the presence of 1 ml of a DMSO containing stem cell product. Vox Sanguinis. 2010; 99(supl. 1): P–1068.
- Pruss A, Mönig HJ. Current standards in tissue banking. ISBT Science Series. 2010; 5(n1): 148–154.
- Nikougoftar-Zarif M, Soleimani M, Abolghasemi H, et al. The effect of micro RNA-10A down regulation in megakaryocytic differentiation of umbilical cord blood CD133+ cells. Vox Sanguinis. 2010; 99(supl. 1): 6B-S49-02.
- Müller-Steinhardt H, Lauber S, Latta M. Evaluation of cryopreserved cord blood units after long-term storage, experience of the Mannheim Cord Blood Bank. Vox Sanguinis. 2010; 99(supl. 1): 6B-S49-03.
- Rebulla P, Giordano R. Regulation of cell based medicine, the European experience. The case of mesenchymal stem cell production for clinical application. Vox Sanguinis. 2010; 99(supl. 1): 5C-S39-02.
- Rojewski M, Dausend J, Schmidtke-Schrezenmeier G, et al. A standardized protocol from GMP compliant expansion of MSC from BM in an animal component free system. Vox Sanguinis. 2010; 99(supl. 1): 4C-S24-02.
- Xia W, Xu X, Fu Y, et al. Comparison of expansion culture conditions between the FCS and HPL in mesenchymal stem cells ex vivo. Vox Sanguinis. 2010; 99(supl. 1): P–1046.
- Peterbaurer-Scherb A, Hildner F, Aberl J, et al. Substitution of fetal calf serum by platelet lysate for culture of adipose derived stem cells. Vox Sanguinis. 2010; 99(supl. 1): P–1055.
- Leitner GC, Faschingbauer M, Fischer G, et al. Does administration of rh-GCSF to healthy volunteers induce epigenetic alteration in lymphocytes? Vox Sanguinis. 2010; 99(supl. 1): 3B-S05-02.
- Hölig K, Kramer M, Blechschmidt M, et al. Peripheral blood stem cell mobilization in healthy related donors — higher risk of mobilization failure? . Vox Sanguinis. 2010; 99(supl. 1): 3B-S05-04.
- Worel N, Rosskopf K, Agis H, et al. Plerixafor plus G-CSF can successfully mobilize CD34+ cells from patients who previously failed chemotherapy and/or cytokine mobilization: the compassionate use experience in Austria. Vox Sanguinis. 2010; 99(supl. 1): 3B-S05-04.
- Worel N, Agis H, et al. D’Addio A. The addition of Plerixafor can rescue PBSC after mobilization in patients with suboptimal CD34 counts after mobilization regimens with chemotherapy and G-CSF. Vox Sanguinis. 2010; 99(supl. 1): P–1082.
- Schrezenmeier H, Feldmann U, Ottinger H, et al. Stem cell transplantation (SCT) for non-malignant disorders: impact of stem cells source and donor type on outcome — analysis of the German registry for stem cell transplantation (DRST). Vox Sanguinis. 2010; 99(supl. 1): 3B-S05-03.
- Kreissig C, Fischer I, Voelker G. Prediction of CD34-cell counts in peripheral blood and stem cell products after G-CSF mobilization in unrelated donors. Vox Sanguinis. 2010; 99(supl. 1): P–1074.
- Wagner U, Wittmann G, Grützner S, et al. Enumeration of CD34+ hematopietic progenitor cells in leukapheresis products for transplantation: comparison of a dual-platform method with a single platform kit. Vox Sanguinis. 2010; 99(supl. 1): P–1055.
